双免疫治疗方案,主要是PD-1抑制剂纳武利尤单抗(Nivolumab, N)+CTLA-4抑制剂伊匹木单抗(Ipilimumab, I)联合方案在晚期NSCLC患者中取得生存获益。. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.